BBLG · Bone Biologics Corp
$1.08
-0.02 (-1.82%)
At close · Jul 23
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern within a reasonable period of time, which is considered to be one year after the date that the financial statements are issued. In addition, our independent registered public accounting firm, in their report on the Company's audited financial statements for the year ended December 31, 2025, expressed substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$1.92M
Shares
1.80M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jeffrey Frelick | CEO | $426,269 |
| Deina H. Walsh | CFO | $263,136 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jeffrey Frelick | CEO | $384,897 |
| Deina H. Walsh | CFO | $242,448 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jeffrey Frelick | CEO | $376,600 |
| Deina H. Walsh | CFO | $238,300 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jeffrey Frelick | CEO | $414,715 |
| Deina H. Walsh | CFO | $250,458 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jeffrey Frelick | CEO | $290,000 |
| Deina H. Walsh | CFO | $21,100 |